Mesenchymal stem cells for ischemic stroke

This study aims to evaluate feasibility and tolerance of intravenous injection of autologous mesenchymal stem cells (MSCs) within less than 6 weeks of an ischemic stroke. In the animal model, biodistribution analyses of the cells demonstrated that they reached the ischemic lesion.